Fobia Sosial

01Pathophysiology

Social phobia is rooted in a dysregulated fear-processing circuit involving the amygdala, prefrontal cortex, and anterior cingulate cortex. The amygdala shows hyperactivation in response to perceived social threat cues, such as angry or judgmental facial expressions. Simultaneously, the prefrontal cortex, which normally exerts top-down inhibition on the amygdala, is functionally underactive. This imbalance means the patient cannot appropriately "downregulate" their fear response in social settings.

At the neurotransmitter level, serotonergic dysfunction plays a central role, which is why SSRIs are effective. There is also evidence of dopaminergic system involvement, particularly in the striatal reward pathways, explaining why social interactions that should be neutral or rewarding are instead experienced as threatening.

The cognitive model, which is critical for understanding the clinical presentation, proposes a self-focused attention bias. When entering a feared social situation, the patient shifts attention inward and constructs a distorted mental image of how they appear to others (e.g., visibly trembling, obviously incompetent). This internal monitoring triggers and sustains autonomic arousal (sweating, blushing, tachycardia), which then becomes the very thing the patient fears others will notice, creating a self-perpetuating feedback loop.

This is why PPDGJ-III criterion (a) emphasizes that the psychological, behavioral, or autonomic symptoms must be the primary manifestation of the anxiety itself, not secondary to another process like delusions or obsessive thoughts. The autonomic symptoms are the direct output of this fear circuit, not a by-product of a different psychiatric mechanism.

Avoidance behavior (criterion c) develops through operant conditioning: escaping or avoiding the feared situation immediately reduces anxiety (negative reinforcement), which strengthens the avoidance pattern over time. This is why avoidance must be a prominent feature for diagnosis, and why exposure-based therapy is a cornerstone of treatment.

02Classification and Clinical Manifestation

Subtypes

Clinical Manifestations by Domain

The anxiety must be dominant in or restricted to social situations outside the family circle (criterion b). Anxiety that occurs equally within and outside the family suggests a different or broader anxiety disorder.

03Diagnostic Workup

The diagnosis of social phobia is entirely clinical. There is no laboratory test or imaging study that confirms it. The PPDGJ-III provides three mandatory criteria that must all be fulfilled:

Criterion (a) requires that the psychological, behavioral, or autonomic symptoms represent the primary manifestation of anxiety, not a secondary phenomenon. This means you must actively exclude that the social avoidance is driven by delusions (as in schizophrenia, where a patient avoids people because of paranoid beliefs) or obsessive thoughts (as in OCD, where avoidance may stem from contamination fears). On the exam, the vignette will usually include a line like "the patient fears others will notice her blushing" or "he avoids meetings because he is afraid of looking foolish." This language points to primary anxiety as the driver.

Criterion (b) specifies that the anxiety must dominate or be confined to social situations outside the family circle. This is a discriminating feature. If the patient is equally anxious at home with family, the diagnosis shifts toward generalized anxiety disorder or possibly agoraphobia.

Criterion (c) requires that avoidance of the phobic situation is or has become a prominent symptom. A patient who fears social situations but does not avoid them (or endure them with only mild distress) may not meet the threshold for diagnosis.

When the clinical picture makes it difficult to differentiate social phobia from agoraphobia, PPDGJ-III instructs you to prioritize the diagnosis of agoraphobia. This is a directly testable rule.

For the workup, thyroid function tests should be considered when the autonomic symptoms (tremor, tachycardia, sweating) are prominent, because hyperthyroidism can closely mimic anxiety. A urine drug screen may be warranted if substance use is suspected, since stimulant or cannabis use can produce social anxiety-like presentations.

04Management and Treatment

Acute Phase (Weeks 1 to 4):
Initiate an SSRI at the lower end of the dosing range (e.g., sertraline 25 to 50 mg/day) to minimize activation side effects such as jitteriness, which can paradoxically worsen anxiety. Counsel the patient that therapeutic benefit typically requires 4 to 6 weeks of consistent dosing. If the patient faces an imminent high-stakes social event (e.g., an important presentation) and has the performance-only subtype, propranolol 10 to 40 mg PRN taken 30 to 60 minutes beforehand can blunt the autonomic symptoms (tremor, tachycardia, sweating) without sedation.

Titration Phase (Weeks 4 to 12):
If the initial dose produces partial response, titrate upward every 2 to 4 weeks. The target dose for sertraline is typically 100 to 200 mg/day. If SSRIs are not tolerated or ineffective after an adequate trial (at least 8 weeks at a therapeutic dose), switch to venlafaxine XR starting at 37.5 to 75 mg/day, titrating to 150 to 225 mg/day.

Psychotherapy:
CBT should be initiated in parallel with or instead of medication, depending on severity and patient preference. The CBT protocol includes cognitive restructuring (identifying and challenging catastrophic predictions about social outcomes) and graduated in-vivo exposure (systematically confronting feared situations in a hierarchical manner). For exam purposes, the combination of SSRI + CBT is superior to either alone in generalized social phobia.

Maintenance Phase:
Continue pharmacotherapy for a minimum of 12 months after achieving remission. Abrupt discontinuation is associated with high relapse rates. Taper SSRIs/SNRIs gradually over 4 to 8 weeks. Patients who completed CBT have lower relapse rates upon medication discontinuation than those treated with medication alone.

Contraindications and Cautions:
Benzodiazepines should be used with caution in patients with a history of substance use disorder. MAOIs (phenelzine) require adherence to a tyramine-free diet and carry the risk of hypertensive crisis. Beta-blockers are contraindicated in asthma and should be used cautiously in diabetes (masking of hypoglycemic symptoms). In pregnancy, SSRIs carry a low but nonzero risk of neonatal adaptation syndrome; paroxetine is generally avoided in the first trimester due to a slightly increased risk of cardiac malformations.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap in questions about social phobia involves the overlap with agoraphobia. A vignette may describe a patient who avoids crowded places, restaurants, or public gatherings. The untrained student fixates on "avoidance of public situations" and selects agoraphobia. The key discriminator is the motive behind the avoidance: if the patient fears embarrassment, humiliation, or judgment by others, it is social phobia; if the patient fears being trapped, unable to escape, or unable to get help during a panic attack, it is agoraphobia. And remember the PPDGJ-III tiebreaker rule: when the distinction is genuinely unclear, the guideline instructs you to favor agoraphobia as the primary diagnosis.

A second common error involves confusing social phobia with avoidant personality disorder. On the exam, social phobia will typically be presented with a clearer onset (often adolescence), situational triggers, and a request for the best initial treatment. Avoidant personality disorder is rarely the "answer" unless the question explicitly asks about personality pathology.

Third, students frequently miss the performance-only subtype and select a full SSRI regimen when the correct answer is PRN propranolol for isolated performance anxiety (e.g., a medical student who freezes during oral exams but functions well in all other social contexts).

The core competency being tested is the ability to identify the central fear of social scrutiny as the driving force behind the symptoms, correctly apply all three PPDGJ-III criteria, and match the treatment to the subtype and severity.